Adage Capital Partners Gp, L.L.C. Syndax Pharmaceuticals Inc Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.9 Billion
- Q4 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 621,840 shares of SNDX stock, worth $10.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
621,840
Previous 817,600
23.94%
Holding current value
$10.2 Million
Previous $15.7 Million
47.77%
% of portfolio
0.01%
Previous 0.03%
Shares
22 transactions
Others Institutions Holding SNDX
# of Institutions
232Shares Held
96.9MCall Options Held
1.39MPut Options Held
543K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$140 Million7.14% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$130 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.95MShares$97.5 Million0.01% of portfolio
-
Morgan Stanley New York, NY5.31MShares$87 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$80 Million0.0% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $927M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...